Lindsley F. Kimball Research Institute (LFKRI) is the research branch of New York Blood Center. Since its establishment in 1964, LFKRI's research efforts have paved the way for new blood-related products, techniques and therapies. The Institute's commitment to ground-breaking research has resulted in numerous landmark patents and licenses.
- Pathogen Inactivation Technology: Created a solvent detergent procedure to inactivate viruses in blood plasm, thereby reducing the risk of hepatitis and HIV transmission through plasma transfusions.
- Cellular Therapy: Demonstrated the feasibility of using cord blood stem cells for transplantation as a treatment option for a number of human diseases.
- HIV Epidemiology: Detailed epidemiological studies on the prevalence of HIV infection in New York City.
- Viral Screening and Vaccine Development: Identified the hepatitis C virus and developed a practical screening method for hepatitis B as well as a safe, effective and affordable vaccine.
- Blood Group Genomics: Molecularly characterized a number of clinically relevant red cell blood group antigens and established donor-recipient genotype matching approach for transfusion.
LFKRI Continues at the Forefront of Blood Disease Research
As one of the preeminent research institutes devoted to blood disease research, LFKRI’s pioneering investigators have a remarkable depth of experience and expertise in their fields and their research programs are supported with funding from federal, state and industrial sources.
- Transfusion Medicine: Developing new molecular approaches and tools to advance safer transfusions
- Hematology: Elucidating molecular and cellular basis of hematological disorders
- Infectious Disease: Discovering new vaccines and prevention strategies against infectious diseases
- Epidemiology: Conducting novel HIV intervention approaches and blood safety surveillance programs
- Cell Therapy: Defining the utility of stem cells in transplantation and regenerative medicine